NRX:CA:TSV-NurExone Biologic Inc. (CAD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.65

Change

0.00 (0.00)%

Market Cap

USD 0.04B

Volume

0.08M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NGEN:CA NervGen Pharma Corp

+0.08 (+3.96%)

USD 0.16B
ARCH:CA Arch Biopartners Inc

+0.02 (+1.19%)

USD 0.11B
MIR:CA MedMira Inc

+0.01 (+5.56%)

USD 0.05B
TTI:CA Thiogenesis Therapeutics Corp.

N/A

USD 0.03B
GSD:CA Devonian Health Group Inc

-0.04 (-16.00%)

USD 0.03B
COV:CA Covalon Technologies Ltd.

+0.04 (+3.92%)

USD 0.03B
CZO:CA Ceapro

+0.01 (+2.04%)

USD 0.02B
KNE:CA Kane Biotech Inc

+0.01 (+3.70%)

USD 0.02B
ZENI-P:CA Zenith Capital Corporation

N/A

USD 0.02B
SBM:CA Sirona Biochem Corp

-0.01 (-7.14%)

USD 0.02B

ETFs Containing NRX:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 120.34% 94% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 120.34% 94% A 94% A
Trailing 12 Months  
Capital Gain 106.35% 100% F 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 106.35% 100% F 95% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 2.67% 65% D 55% F
Dividend Return 2.67% 65% D 55% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 47.38% 52% F 51% F
Risk Adjusted Return 5.63% 65% D 55% F
Market Capitalization 0.04B 87% B+ 80% B-

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.